Fig. 4.
Fig. 4. Cytokine activation of NF-κB in CD34+CD19− bone marrow cells. Human CD34+CD19− bone marrow was purified and incubated for 18 hours at 37°C with each cytokine/peptide combination and EMSA was performed. (A) TNF-, (B) GM-CSF, (C) IL-3, and (E) a combination of GM-CSF, IL-3, SCF, and EPO activated NF-κB and its nuclear translocation could be blocked by the NF-κB NLS peptide. (D) M-CSF and G-CSF did not activate NF-κB. The purity of the CD34+CD19− cells for experiments (A) through (E) was 99.1%, 98.7%, 96.8%, 95.6%, and 98.6%, respectively.

Cytokine activation of NF-κB in CD34+CD19 bone marrow cells. Human CD34+CD19 bone marrow was purified and incubated for 18 hours at 37°C with each cytokine/peptide combination and EMSA was performed. (A) TNF-, (B) GM-CSF, (C) IL-3, and (E) a combination of GM-CSF, IL-3, SCF, and EPO activated NF-κB and its nuclear translocation could be blocked by the NF-κB NLS peptide. (D) M-CSF and G-CSF did not activate NF-κB. The purity of the CD34+CD19 cells for experiments (A) through (E) was 99.1%, 98.7%, 96.8%, 95.6%, and 98.6%, respectively.

Close Modal

or Create an Account

Close Modal
Close Modal